Public court records · Regulatory sources · Independently maintained Data as of: 2026-09-29 · Not legal advice

Zantac (Ranitidine NDMA) Lawsuit

US Archived Last verified 2026-09-29

S.D. Fla.

Claims alleged that NDMA contamination in Zantac (ranitidine) caused cancer..

This case record is archived. The litigation has concluded (settlement finalized / claims resolved). We keep the page public as a reference — no new case reviews are accepted for this matter.

Overview

Claims alleged that NDMA contamination in Zantac (ranitidine) caused cancer. The FDA ordered the withdrawal of all ranitidine products in September 2020 (per FDA). State claims were resolved in 2024: GSK up to $2.2 billion (~80,000 claims, ~93%, per public reports) and Sanofi up to $350 million (per public reports). In the federal MDL (S.D. Fla.), the court dismissed the cases in December 2022 and plaintiffs appealed (per court records). The matter is archived — no new intake.

Companies involved

Settlement amounts

GSK: up to $2.2 billion for ~80,000 state claims (~93%, per public reports, Oct 2024). Sanofi: up to $350 million (per public reports, May 2024). Federal MDL: dismissed Dec 2022, on appeal (per court records). No new intake.

Figures above are as reported by the cited sources — not a promise of any individual outcome.

Last updated: 2024-10-01

Full breakdown: settlement amounts page →

Key dates

  1. October 1, 2024GSK agrees to up to $2.2 billion for ~80,000 state claims (~93%) (per public reports)
  2. May 1, 2024Sanofi agrees to up to $350 million for ~14,000 state claims (per public reports)
  3. December 1, 2022Judge dismisses the federal MDL cases; plaintiffs appeal (per court records)
  4. September 11, 2020FDA orders withdrawal of all ranitidine products from the U.S. market (per FDA)

Notable filings

No notable filings recorded yet. Docket entries are added from public court records as they appear.

FAQ

Frequently asked questions about this case record, answered from the public record.

What is the Zantac lawsuit about?

Claims alleged that NDMA (N-nitrosodimethylaniline) contamination in Zantac (ranitidine) caused cancer (per complaints). The federal MDL was In re Ranitidine Products Liability Litigation, S.D. Fla.

Why was Zantac pulled from the market?

The FDA ordered the withdrawal of all ranitidine products in September 2020 after NDMA contamination concerns (per FDA).

How much did the settlements pay?

State claims were resolved in 2024: GSK up to $2.2 billion covering about 80,000 claims (roughly 93% of claimants, per public reports, October 2024), and Sanofi up to $350 million (per public reports, May 2024).

What happened in the federal MDL?

In the federal MDL (S.D. Fla.), the court dismissed the cases in December 2022 and plaintiffs appealed (per court records).

Can I still file a Zantac claim?

The state settlements resolved the large majority of claimants (per public reports, 2024). For any remaining position — for example, on the federal appeals — consult a licensed attorney. This page is reference only.

Why is this page archived?

The litigation has concluded for practical purposes (state settlements finalized 2024, per public reports). We keep the record public because “zantac settlement” remains a frequently searched, reference-worthy record.

Case record — archived

This page is neutral reference material — not legal advice. The litigation for this matter has concluded, so case reviews are closed. For advice on your own situation, contact a licensed attorney in your country.